Skip to main navigation Skip to search Skip to main content

6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integrase

Research output: Contribution to journalArticlepeer-review

Abstract

N-3-Hydroxylation of pyrimidine-2,4-diones was recently found to yield inhibitors of both HIV-1 reverse transcriptase (RT) and integrase (IN). An extended series of analogues featuring a benzoyl group at the C-6 position of the pyrimidine ring was synthesized. Through biochemical studies it was found that these new analogues are dually active against both RT and IN in low micromolar range. Antiviral assays confirmed that these new inhibitors are active against HIV-1 in cell culture at nanomolar to low micromolar range, further validating 3-hydroxypyrimidine-2,4-diones as a viable scaffold for antiviral development.

Original languageEnglish (US)
Pages (from-to)2400-2402
Number of pages3
JournalBioorganic and Medicinal Chemistry Letters
Volume21
Issue number8
DOIs
StatePublished - Apr 15 2011

Bibliographical note

Funding Information:
This research was supported by the Center for Drug Design at the University of Minnesota, by the Center for Cancer Research, National Cancer Institute, NIH, and by an NIH-IATAP grant to Y.P. and K.M. We thank Roger Ptak at Southern Research Institute for antiviral assays and the Minnesota Supercomputing Institute for modeling resources.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • 6-Benzoyl-3-hydroxypyrimidine-2,4-diones
  • Dual inhibitors
  • HIV
  • Integrase
  • Reverse transcriptase

Fingerprint

Dive into the research topics of '6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integrase'. Together they form a unique fingerprint.

Cite this